TICKERNERD
Menu
JBIOJBIOHealthcare · Biotechnology

JBIO Stock Forecast: Jade Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$21
+0.61% on the day

The 10 Wall Street analysts covering Jade Biosciences, Inc. hold a median 12-month price target of $47 — +120.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
25 / 100
Median analyst target
$47
Analysts covering
10
Total return, dividends reinvested
1W
−13.6%
1M
+4.0%
YTD
+38.4%
1Y
+189.4%
From 52W high
−20.4%
From 52W low
+207.3%
$7
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jade Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Quality
56
Value
55
Size
41
Growth
28
Revisions
28
Issuance
26
Accruals
26
Volatility
20

Momentum (83): The shares have been drifting up relative to others.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26JBIOHigh $77Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $40Median $47High $77

The green dot is the last close — the median target sits +120.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026WedbushMaintainsOutperform$45 → $47
10 Aug 2026BTIGMaintainsBuy$74 → $77
15 June 2026UBSInitiatesBuy$45
15 June 2026UBSInitiatesBuy—
2 June 2026WedbushMaintainsOutperform—
1 June 2026BTIGMaintainsBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
27 May 2026BTIGReiteratesBuy—
11 May 2026GuggenheimMaintainsBuy—
11 May 2026WedbushMaintainsOutperform—
27 Apr 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026BTIGMaintainsBuy—
11 Mar 2026GuggenheimMaintainsBuy—
9 Mar 2026WedbushReiteratesOutperform—
7 Jan 2026HC Wainwright & Co.InitiatesBuy—
25 Nov 2025Clear StreetInitiatesBuy—
18 Nov 2025GuggenheimMaintainsBuy—
9 Oct 2025BTIGInitiatesBuy—
14 Aug 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

JBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Jade Biosciences, Inc. (JBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.7×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
−5.4×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.3%

Higher than 24% of US stocks

Return on assets
−36.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

JBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JBIOJade Biosciences, Inc.$1.4B
25
OMEROmeros Corp.$1.4B
91
VORVor Biopharma, Inc.$1.4B
15
ANROAlto Neuroscience, Inc.$1.3B
57
CGEMCullinan Therapeutics, Inc.$1.3B
71
AKTSAktis Oncology, Inc.$1.3B
2
MGTXMeiragtx Holdings plc$1.3B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jade Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JBIO news & analysis

Jade Biosciences: Duration Is The Real Product

Seeking Alpha · 19 Aug 2026positive

Seeking Alpha's coverage highlights Jade Biosciences' focus on IgAN with lead candidate JADE101, designed for quarterly dosing to improve patient adherence versus competitors' more frequent regimens. Phase 1 data showed roughly 70% IgA reduction with a favorable safety profile, with pivotal Phase 2 JUNIPER interim data expected in 2027, alongside a pipeline of JADE201 and JADE301 engineered for extended-interval dosing.

Why it matters — JBIO watchers would care because the company's extended-interval dosing strategy across its pipeline is positioned as a key differentiator in validated autoimmune markets, with Phase 1 efficacy and safety data supporting its lead IgAN candidate.

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 10 Aug 2026positive

Jade Biosciences reported second quarter 2026 financial results and a corporate update, highlighting positive interim Phase 1 data for JADE101 in IgA nephropathy, ongoing Phase 2 and planned Phase 3 trials, the start of a Phase 1 trial for JADE201 in rheumatoid arthritis, and a revised timeline for JADE301's Phase 1 trial. The company had $461 million in cash as of June 30, 2026, expected to fund operations into the fourth quarter of 2028.

Why it matters — The release provides JBIO watchers with updates on the clinical progress and timelines of its lead pipeline candidates as well as its cash runway.

FAQ

Frequently asked questions about JBIO stock

What is the JBIO stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Jade Biosciences, Inc. have a median 12-month price target of $47, with estimates ranging from $40 to $77. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JBIO stock a buy right now?

Of the 10 analysts covering Jade Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jade Biosciences, Inc. 25 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JBIO?

As at 22 Aug 2026, Jade Biosciences, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will JBIO stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +120.0% from the last close, and Ticker Nerd's factor model ranks Jade Biosciences, Inc. 25 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JBIO stock forecast for 2030?

No analyst covering Jade Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $77 over the next 12 months.

How has JBIO stock performed over the past year?

Jade Biosciences, Inc. returned +189.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jade Biosciences, Inc. do?

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases.

What is the latest news on JBIO?

The most recent item we track (Seeking Alpha, 19 Aug 2026): "Jade Biosciences: Duration Is The Real Product". Seeking Alpha's coverage highlights Jade Biosciences' focus on IgAN with lead candidate JADE101, designed for quarterly dosing to improve patient adherence versus competitors' more frequent regimens. Phase 1 data showed roughly 70% IgA reduction with a favorable safety profile, with pivotal Phase 2 JUNIPER interim data expected in 2027, alongside a pipeline of JADE201 and JADE301 engineered for extended-interval dosing.

Company

About Jade Biosciences, Inc.

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and targets immunoglobulin A nephropathy (IgAN), a chronic kidney disease that damages kidney function by promoting harmful IgA antibodies and proteinuria. The company's pipeline also features JADE201, an anti-BAFF-R (B-cell activating factor receptor) program, and JADE301, an undisclosed antibody initiative, all aimed at creating potentially best-in-class, disease-modifying biologics. Jade Biosciences Inc. builds on discovery-stage assets licensed from Paragon Therapeutics to address critical unmet needs in autoimmune conditions. Incorporated in 2024 and headquartered in Waltham, Massachusetts, the company operates in the healthcare sector, advancing its programs through clinical trials including ongoing Phase 1 studies for JADE101 with planned Phase 2 initiation.

CEO Mr. Tom Frohlich · 55 employees · United States · https://jadebiosciences.com